Last 12 months
Inside the activity.
0 purchase rows · 35 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 2 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 16 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 17 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 13, 2022 Filed Jun 30, 2023 20:04 UTC |
Romanelli JosephPresident, Human Health Int?l
|
PurchaseCommon Stock | 56 | $110.96 | $6,213.76 |
DisclosureSEC source: 0001127602-23-019612 · form4.xml · nonDerivative · entry 4 Romanelli Joseph · CIK 0001938322 · President, Human Health Int?l 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,477.325 F1 · shares: None of the purchases or sales reported herein were directed by the reporting person, but were executed by a brokerage firm for the benefit of the reporting person's managed account, without the reporting person's knowledge. One of the reported transactions resulted in a short swing profit under Section 16(b) of the Securities Exchange Act of 1934, as amended ("Section 16(b)"), and the reporting person has disgorged $374.01 to the Issuer, which amount represents all profits related to these transactions in accordance with Section 16(b). Read SEC document |
| December 06, 2022 Filed Jun 30, 2023 20:04 UTC |
Romanelli JosephPresident, Human Health Int?l
|
PurchaseCommon Stock | 30 | $109.39 | $3,281.70 |
DisclosureSEC source: 0001127602-23-019612 · form4.xml · nonDerivative · entry 3 Romanelli Joseph · CIK 0001938322 · President, Human Health Int?l 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,421.325 F1 · shares: None of the purchases or sales reported herein were directed by the reporting person, but were executed by a brokerage firm for the benefit of the reporting person's managed account, without the reporting person's knowledge. One of the reported transactions resulted in a short swing profit under Section 16(b) of the Securities Exchange Act of 1934, as amended ("Section 16(b)"), and the reporting person has disgorged $374.01 to the Issuer, which amount represents all profits related to these transactions in accordance with Section 16(b). Read SEC document |
| December 05, 2022 Filed Jun 30, 2023 20:04 UTC |
Romanelli JosephPresident, Human Health Int?l
|
PurchaseCommon Stock | 107 | $109.54 | $11,720.78 |
DisclosureSEC source: 0001127602-23-019612 · form4.xml · nonDerivative · entry 2 Romanelli Joseph · CIK 0001938322 · President, Human Health Int?l 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,391.325 F1 · shares: None of the purchases or sales reported herein were directed by the reporting person, but were executed by a brokerage firm for the benefit of the reporting person's managed account, without the reporting person's knowledge. One of the reported transactions resulted in a short swing profit under Section 16(b) of the Securities Exchange Act of 1934, as amended ("Section 16(b)"), and the reporting person has disgorged $374.01 to the Issuer, which amount represents all profits related to these transactions in accordance with Section 16(b). Read SEC document |
| December 02, 2022 Filed Jun 30, 2023 20:04 UTC |
Romanelli JosephPresident, Human Health Int?l
|
PurchaseCommon Stock | 59 | $109.67 | $6,470.53 |
DisclosureSEC source: 0001127602-23-019612 · form4.xml · nonDerivative · entry 1 Romanelli Joseph · CIK 0001938322 · President, Human Health Int?l 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 59 F1 · shares: None of the purchases or sales reported herein were directed by the reporting person, but were executed by a brokerage firm for the benefit of the reporting person's managed account, without the reporting person's knowledge. One of the reported transactions resulted in a short swing profit under Section 16(b) of the Securities Exchange Act of 1934, as amended ("Section 16(b)"), and the reporting person has disgorged $374.01 to the Issuer, which amount represents all profits related to these transactions in accordance with Section 16(b). Read SEC document |
| November 10, 2022 Filed Nov 10, 2022 22:01 UTC |
MIZELL STEVENEVP, Chief HR Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $70.71 | $0.00 |
DisclosureSEC source: 0001127602-22-025313 · form4.xml · derivative · entry 6 MIZELL STEVEN · CIK 0001189403 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 824 Underlying: Common Stock · 15,000 shares Expires 2028-10-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested and became exercisable in three equal installments on 10/30/2019, 10/30/2020 and 10/30/2021. Read SEC document |
| November 10, 2022 Filed Nov 10, 2022 22:01 UTC |
MIZELL STEVENEVP, Chief HR Officer
|
SaleCommon Stock | 15,000 | $101.42 | $1,521,277.50 |
DisclosureSEC source: 0001127602-22-025313 · form4.xml · nonDerivative · entry 4 MIZELL STEVEN · CIK 0001189403 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,144.145 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $101.4000 to $101.5300, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| November 10, 2022 Filed Nov 10, 2022 22:01 UTC |
MIZELL STEVENEVP, Chief HR Officer
|
Exercise / conversionCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-025313 · form4.xml · nonDerivative · entry 3 MIZELL STEVEN · CIK 0001189403 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,144.145 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 09, 2022 Filed Nov 10, 2022 21:42 UTC |
Davis Robert MDirector · CEO & President
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 167,613 | $0.00 Strike: $62.07 | $0.00 |
DisclosureSEC source: 0001127602-22-025304 · form4.xml · derivative · entry 5 Davis Robert M · CIK 0001363076 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 167,613 shares Expires 2027-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. F5 · derivative.exercise_date: The option became exercisable in equal installments on 5/5/2018, 5/5/2019 and 5/5/2020. F4 · balance_after: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. Read SEC document |
| November 09, 2022 Filed Nov 10, 2022 21:42 UTC |
Davis Robert MDirector · CEO & President
|
SaleCommon Stock | 100 | $103.59 | $10,359.00 |
DisclosureSEC source: 0001127602-22-025304 · form4.xml · nonDerivative · entry 4 Davis Robert M · CIK 0001363076 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 247,592.757 F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| November 09, 2022 Filed Nov 10, 2022 21:42 UTC |
Davis Robert MDirector · CEO & President
|
SaleCommon Stock | 79,918 | $102.98 | $8,229,923.67 |
DisclosureSEC source: 0001127602-22-025304 · form4.xml · nonDerivative · entry 3 Davis Robert M · CIK 0001363076 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 247,692.757 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $102.5600 to $103.5600, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Read SEC document |
| November 09, 2022 Filed Nov 10, 2022 21:42 UTC |
Davis Robert MDirector · CEO & President
|
SaleCommon Stock | 87,595 | $101.94 | $8,929,556.93 |
DisclosureSEC source: 0001127602-22-025304 · form4.xml · nonDerivative · entry 2 Davis Robert M · CIK 0001363076 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 327,610.757 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $101.5500 to $102.5500, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Read SEC document |
| November 09, 2022 Filed Nov 10, 2022 21:42 UTC |
Davis Robert MDirector · CEO & President
|
Exercise / conversionCommon Stock | 167,613 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-025304 · form4.xml · nonDerivative · entry 1 Davis Robert M · CIK 0001363076 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 415,205.757 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 09, 2022 Filed Nov 10, 2022 21:44 UTC |
Oosthuizen Johannes JacobusPresident, U.S. Market
|
SaleCommon Stock | 1,795 | $103.21 | $185,261.95 |
DisclosureSEC source: 0001127602-22-025307 · form4.xml · nonDerivative · entry 1 Oosthuizen Johannes Jacobus · CIK 0001916310 · President, U.S. Market 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,730.881 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| November 08, 2022 Filed Nov 10, 2022 22:01 UTC |
MIZELL STEVENEVP, Chief HR Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $70.71 | $0.00 |
DisclosureSEC source: 0001127602-22-025313 · form4.xml · derivative · entry 5 MIZELL STEVEN · CIK 0001189403 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,824 Underlying: Common Stock · 20,000 shares Expires 2028-10-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested and became exercisable in three equal installments on 10/30/2019, 10/30/2020 and 10/30/2021. Read SEC document |
| November 08, 2022 Filed Nov 10, 2022 22:01 UTC |
MIZELL STEVENEVP, Chief HR Officer
|
SaleCommon Stock | 20,000 | $101.00 | $2,020,000.00 |
DisclosureSEC source: 0001127602-22-025313 · form4.xml · nonDerivative · entry 2 MIZELL STEVEN · CIK 0001189403 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,144.145 Read SEC document |
| November 08, 2022 Filed Nov 10, 2022 22:01 UTC |
MIZELL STEVENEVP, Chief HR Officer
|
Exercise / conversionCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-025313 · form4.xml · nonDerivative · entry 1 MIZELL STEVEN · CIK 0001189403 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,144.145 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 07, 2022 Filed Nov 7, 2022 21:09 UTC |
Oosthuizen Johannes JacobusPresident, U.S. Market
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 7,045 | $0.00 Strike: $73.73 | $0.00 |
DisclosureSEC source: 0001127602-22-025022 · form4.xml · derivative · entry 9 Oosthuizen Johannes Jacobus · CIK 0001916310 · President, U.S. Market 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,094 Underlying: Common Stock · 7,045 shares Expires 2031-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The options become exercisable in three equal installments on 5/4/2022, 5/4/2023 and 5/4/2024. Read SEC document |
| November 07, 2022 Filed Nov 7, 2022 21:09 UTC |
Oosthuizen Johannes JacobusPresident, U.S. Market
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 13,540 | $0.00 Strike: $75.36 | $0.00 |
DisclosureSEC source: 0001127602-22-025022 · form4.xml · derivative · entry 8 Oosthuizen Johannes Jacobus · CIK 0001916310 · President, U.S. Market 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,773 Underlying: Common Stock · 13,540 shares Expires 2030-04-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The options become exercisable in three equal installments on 5/1/2021, 5/1/2022 and 5/1/2023. Read SEC document |
| November 07, 2022 Filed Nov 7, 2022 21:09 UTC |
Oosthuizen Johannes JacobusPresident, U.S. Market
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 17,455 | $0.00 Strike: $77.62 | $0.00 |
DisclosureSEC source: 0001127602-22-025022 · form4.xml · derivative · entry 7 Oosthuizen Johannes Jacobus · CIK 0001916310 · President, U.S. Market 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,455 shares Expires 2029-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The options became exercisable in three equal installments on 5/3/2020, 5/3/2021 and 5/3/2022. Read SEC document |
| November 07, 2022 Filed Nov 7, 2022 21:09 UTC |
Oosthuizen Johannes JacobusPresident, U.S. Market
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 14,703 | $0.00 Strike: $62.07 | $0.00 |
DisclosureSEC source: 0001127602-22-025022 · form4.xml · derivative · entry 6 Oosthuizen Johannes Jacobus · CIK 0001916310 · President, U.S. Market 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,703 shares Expires 2027-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The options became exercisable in three equal installments on 5/5/2018, 5/5/2019, and 5/5/2020. Read SEC document |
| November 07, 2022 Filed Nov 7, 2022 21:09 UTC |
Oosthuizen Johannes JacobusPresident, U.S. Market
|
SaleCommon Stock | 45,561 | $99.47 | $4,531,980.01 |
DisclosureSEC source: 0001127602-22-025022 · form4.xml · nonDerivative · entry 5 Oosthuizen Johannes Jacobus · CIK 0001916310 · President, U.S. Market 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,525.881 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.3700 to $99.5800, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| November 07, 2022 Filed Nov 7, 2022 21:09 UTC |
Oosthuizen Johannes JacobusPresident, U.S. Market
|
Exercise / conversionCommon Stock | 7,045 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-025022 · form4.xml · nonDerivative · entry 4 Oosthuizen Johannes Jacobus · CIK 0001916310 · President, U.S. Market 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,086.881 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 07, 2022 Filed Nov 7, 2022 21:09 UTC |
Oosthuizen Johannes JacobusPresident, U.S. Market
|
Exercise / conversionCommon Stock | 13,540 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-025022 · form4.xml · nonDerivative · entry 3 Oosthuizen Johannes Jacobus · CIK 0001916310 · President, U.S. Market 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,041.881 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 07, 2022 Filed Nov 7, 2022 21:09 UTC |
Oosthuizen Johannes JacobusPresident, U.S. Market
|
Exercise / conversionCommon Stock | 17,455 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-025022 · form4.xml · nonDerivative · entry 2 Oosthuizen Johannes Jacobus · CIK 0001916310 · President, U.S. Market 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,501.881 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 07, 2022 Filed Nov 7, 2022 21:09 UTC |
Oosthuizen Johannes JacobusPresident, U.S. Market
|
Exercise / conversionCommon Stock | 14,703 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-025022 · form4.xml · nonDerivative · entry 1 Oosthuizen Johannes Jacobus · CIK 0001916310 · President, U.S. Market 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,046.881 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 07, 2022 Filed Nov 8, 2022 21:56 UTC |
FRAZIER KENNETH CDirector · Executive Chair
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 235,769 | $0.00 Strike: $53.06 | $0.00 |
DisclosureSEC source: 0001127602-22-025118 · form4.xml · derivative · entry 6 FRAZIER KENNETH C · CIK 0001181175 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 235,769 shares Expires 2026-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option became exercisable in equal installments on 5/10/2017, 5/10/2018 and 5/10/2019. Read SEC document |
| November 07, 2022 Filed Nov 8, 2022 21:56 UTC |
FRAZIER KENNETH CDirector · Executive Chair
|
SaleCommon Stock | 84,721 | $100.07 | $8,477,717.00 |
DisclosureSEC source: 0001127602-22-025118 · form4.xml · nonDerivative · entry 4 FRAZIER KENNETH C · CIK 0001181175 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 700,653.063 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.7600 to $100.3400, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F4 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| November 07, 2022 Filed Nov 8, 2022 21:56 UTC |
FRAZIER KENNETH CDirector · Executive Chair
|
SaleCommon Stock | 126,134 | $99.42 | $12,540,835.11 |
DisclosureSEC source: 0001127602-22-025118 · form4.xml · nonDerivative · entry 3 FRAZIER KENNETH C · CIK 0001181175 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 785,374.063 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.7500 to $99.7500, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Read SEC document |
| November 07, 2022 Filed Nov 8, 2022 21:56 UTC |
FRAZIER KENNETH CDirector · Executive Chair
|
SaleCommon Stock | 24,914 | $98.45 | $2,452,880.46 |
DisclosureSEC source: 0001127602-22-025118 · form4.xml · nonDerivative · entry 2 FRAZIER KENNETH C · CIK 0001181175 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 911,508.063 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $97.7400 to $98.7400, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Read SEC document |
| November 07, 2022 Filed Nov 8, 2022 21:56 UTC |
FRAZIER KENNETH CDirector · Executive Chair
|
Exercise / conversionCommon Stock | 235,769 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-025118 · form4.xml · nonDerivative · entry 1 FRAZIER KENNETH C · CIK 0001181175 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 936,422.063 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 04, 2022 Filed Nov 7, 2022 21:06 UTC |
FRAZIER KENNETH CDirector · Executive Chair
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 235,000 | $0.00 Strike: $53.06 | $0.00 |
DisclosureSEC source: 0001127602-22-025018 · form4.xml · derivative · entry 9 FRAZIER KENNETH C · CIK 0001181175 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,769 Underlying: Common Stock · 235,000 shares Expires 2026-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option became exercisable in equal installments on 5/10/2017, 5/10/2018 and 5/10/2019. Read SEC document |
| November 04, 2022 Filed Nov 7, 2022 21:06 UTC |
FRAZIER KENNETH CDirector · Executive Chair
|
SaleCommon Stock | 34,810 | $99.08 | $3,448,988.72 |
DisclosureSEC source: 0001127602-22-025018 · form4.xml · nonDerivative · entry 6 FRAZIER KENNETH C · CIK 0001181175 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 700,653.063 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.9800 to $99.2800, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F5 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| November 04, 2022 Filed Nov 7, 2022 21:06 UTC |
FRAZIER KENNETH CDirector · Executive Chair
|
SaleCommon Stock | 200,190 | $98.53 | $19,725,241.19 |
DisclosureSEC source: 0001127602-22-025018 · form4.xml · nonDerivative · entry 5 FRAZIER KENNETH C · CIK 0001181175 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 735,463.063 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $97.9700 to $98.9700, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Read SEC document |
| November 04, 2022 Filed Nov 7, 2022 21:06 UTC |
FRAZIER KENNETH CDirector · Executive Chair
|
Exercise / conversionCommon Stock | 235,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-025018 · form4.xml · nonDerivative · entry 4 FRAZIER KENNETH C · CIK 0001181175 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 935,653.063 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 03, 2022 Filed Nov 7, 2022 21:06 UTC |
FRAZIER KENNETH CDirector · Executive Chair
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 235,000 | $0.00 Strike: $53.06 | $0.00 |
DisclosureSEC source: 0001127602-22-025018 · form4.xml · derivative · entry 8 FRAZIER KENNETH C · CIK 0001181175 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 470,769 Underlying: Common Stock · 235,000 shares Expires 2026-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option became exercisable in equal installments on 5/10/2017, 5/10/2018 and 5/10/2019. Read SEC document |
| November 03, 2022 Filed Nov 7, 2022 21:06 UTC |
FRAZIER KENNETH CDirector · Executive Chair
|
SaleCommon Stock | 20,383 | $99.09 | $2,019,804.47 |
DisclosureSEC source: 0001127602-22-025018 · form4.xml · nonDerivative · entry 3 FRAZIER KENNETH C · CIK 0001181175 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 700,653.063 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.0600 to $99.2000, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Read SEC document |
| November 03, 2022 Filed Nov 7, 2022 21:06 UTC |
FRAZIER KENNETH CDirector · Executive Chair
|
SaleCommon Stock | 214,617 | $98.68 | $21,178,083.63 |
DisclosureSEC source: 0001127602-22-025018 · form4.xml · nonDerivative · entry 2 FRAZIER KENNETH C · CIK 0001181175 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 721,036.063 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.0500 to $99.0500, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Read SEC document |
| November 03, 2022 Filed Nov 7, 2022 21:06 UTC |
FRAZIER KENNETH CDirector · Executive Chair
|
Exercise / conversionCommon Stock | 235,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-025018 · form4.xml · nonDerivative · entry 1 FRAZIER KENNETH C · CIK 0001181175 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 935,653.063 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 02, 2022 Filed Nov 3, 2022 20:06 UTC |
FRAZIER KENNETH CDirector · Executive Chair
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 134,172 | $0.00 Strike: $53.06 | $0.00 |
DisclosureSEC source: 0001127602-22-024871 · form4.xml · derivative · entry 15 FRAZIER KENNETH C · CIK 0001181175 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 705,769 Underlying: Common Stock · 134,172 shares Expires 2026-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_price: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. F10 · derivative.exercise_date: The option became exercisable in equal installments on 5/10/2017, 5/10/2018 and 5/10/2019. F9 · balance_after: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. Read SEC document |
| November 02, 2022 Filed Nov 3, 2022 20:06 UTC |
FRAZIER KENNETH CDirector · Executive Chair
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 165,828 | $0.00 Strike: $58.08 | $0.00 |
DisclosureSEC source: 0001127602-22-024871 · form4.xml · derivative · entry 14 FRAZIER KENNETH C · CIK 0001181175 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 165,828 shares Expires 2025-04-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The option became exercisable in equal installments on 5/1/2016, 5/1/2017 and 5/1/2018. Read SEC document |
| November 02, 2022 Filed Nov 3, 2022 20:06 UTC |
FRAZIER KENNETH CDirector · Executive Chair
|
SaleCommon Stock | 94,339 | $100.40 | $9,471,739.37 |
DisclosureSEC source: 0001127602-22-024871 · form4.xml · nonDerivative · entry 11 FRAZIER KENNETH C · CIK 0001181175 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 700,653.063 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $100.0100 to $101.0100, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F6 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| November 02, 2022 Filed Nov 3, 2022 20:06 UTC |
FRAZIER KENNETH CDirector · Executive Chair
|
SaleCommon Stock | 205,661 | $99.68 | $20,500,103.39 |
DisclosureSEC source: 0001127602-22-024871 · form4.xml · nonDerivative · entry 10 FRAZIER KENNETH C · CIK 0001181175 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 794,992.063 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.0000 to $100.0000, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Read SEC document |
| November 02, 2022 Filed Nov 3, 2022 20:06 UTC |
FRAZIER KENNETH CDirector · Executive Chair
|
Exercise / conversionCommon Stock | 134,172 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-024871 · form4.xml · nonDerivative · entry 9 FRAZIER KENNETH C · CIK 0001181175 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000,653.063 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 02, 2022 Filed Nov 3, 2022 20:06 UTC |
FRAZIER KENNETH CDirector · Executive Chair
|
Exercise / conversionCommon Stock | 165,828 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-024871 · form4.xml · nonDerivative · entry 8 FRAZIER KENNETH C · CIK 0001181175 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 866,481.063 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 01, 2022 Filed Nov 3, 2022 20:06 UTC |
FRAZIER KENNETH CDirector · Executive Chair
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $58.08 | $0.00 |
DisclosureSEC source: 0001127602-22-024871 · form4.xml · derivative · entry 13 FRAZIER KENNETH C · CIK 0001181175 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,828 Underlying: Common Stock · 300,000 shares Expires 2025-04-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The option became exercisable in equal installments on 5/1/2016, 5/1/2017 and 5/1/2018. Read SEC document |
| November 01, 2022 Filed Nov 3, 2022 20:06 UTC |
FRAZIER KENNETH CDirector · Executive Chair
|
GiftCommon Stock | 1,470 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-024871 · form4.xml · nonDerivative · entry 7 FRAZIER KENNETH C · CIK 0001181175 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 700,653.063 Read SEC document |
| November 01, 2022 Filed Nov 3, 2022 20:06 UTC |
FRAZIER KENNETH CDirector · Executive Chair
|
GiftCommon Stock | 2,450 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-024871 · form4.xml · nonDerivative · entry 6 FRAZIER KENNETH C · CIK 0001181175 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 702,123.063 Read SEC document |
| November 01, 2022 Filed Nov 3, 2022 20:06 UTC |
FRAZIER KENNETH CDirector · Executive Chair
|
GiftCommon Stock | 1,710 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-024871 · form4.xml · nonDerivative · entry 5 FRAZIER KENNETH C · CIK 0001181175 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 704,573.063 Read SEC document |
| November 01, 2022 Filed Nov 3, 2022 20:06 UTC |
FRAZIER KENNETH CDirector · Executive Chair
|
SaleCommon Stock | 700 | $101.05 | $70,732.97 |
DisclosureSEC source: 0001127602-22-024871 · form4.xml · nonDerivative · entry 4 FRAZIER KENNETH C · CIK 0001181175 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 706,283.063 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $101.0300 to $101.0700, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Read SEC document |
| November 01, 2022 Filed Nov 3, 2022 20:06 UTC |
FRAZIER KENNETH CDirector · Executive Chair
|
SaleCommon Stock | 96,981 | $100.22 | $9,719,843.14 |
DisclosureSEC source: 0001127602-22-024871 · form4.xml · nonDerivative · entry 3 FRAZIER KENNETH C · CIK 0001181175 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 706,983.063 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.9800 to $100.9800, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.